XHXu He

Xu He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xu He has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Boxiang Zhao

    Department of Interventional and Vascular Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, PR China

    11 shared publications
  • Jie Kong

    Department of Interventional and Vascular Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, P.R. China

    10 shared publications
  • Maofeng Gong

    Nanjing Med Univ, Nanjing Hosp 1, Dept Intervent Radiol, Nanjing, Jiangsu, Peoples R China

    9 shared publications
  • Zhengli Liu

    Department of Interventional and Vascular Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, P.R. China

    9 shared publications
  • Jianping Gu

    Department of Interventional and Vascular Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, P.R. China

    8 shared publications
  • Guanqi Fu

    Nanjing Med Univ, Nanjing Hosp 1, Dept Intervent Radiol, Nanjing, Jiangsu, Peoples R China

    7 shared publications

Latest Publications

  • Open Access

    Comparative Efficacy and Safety of Reperfusion Strategies for Acute Intermediate-Risk Pulmonary Embolism: A Systematic Review and Network Meta-Analysis of Randomised Trials

    by Jie Kong, Liu Zhengli, Gong Maofeng, Jiang Rui, Xie Liwei, Zhao Boxiang, Lu Zhaoxuan, Zhou Yangyi, Chen Liang, Su Haobo, et al.

    Background: The optimal initial reperfusion strategy for acute intermediate-risk pulmonary embolism remains uncertain. We compared anticoagulation, systemic thrombolysis, catheter-directed thrombolysis, ultrasound-assisted catheter-directed thrombolysis, large-bore aspiration thrombectomy, and catheter-assisted aspiration thrombectomy in a risk-stratified network meta-analysis of randomised trials.Methods: The protocol was registered with PROSPERO (CRD420261417361).We searched PubMed/MEDLINE, Embase, CENTRAL, Web of Science, CNKI, Wanfang, VIP, SinoMed, ClinicalTrials.gov, and WHO ICTRP from inception to May 11, 2026, without language restrictions. Eligible studies were randomised controlled trials in adults with acute intermediate-risk pulmonary embolism. NMA-2 was the primary intermediate-high-risk network; NMA-3 was an all-intermediate-risk validation network. Frequentist random-effects network meta-analysis estimated odds ratios (ORs) and 95% CIs for five core binary outcomes. Certainty was assessed with RoB 2.0 and CINeMA/GRADE.Findings: Nineteen trials including 3548 participants were included. In NMA-2, systemic thrombolysis and ultrasound-assisted catheter-directed thrombolysis reduced clinical deterioration versus anticoagulation alone (systemic thrombolysis: OR 0.36, 95% CI 0.17-0.76; ultrasound-assisted catheter-directed thrombolysis: OR 0.33, 0.16-0.66) and treatment escalation or rescue reperfusion (systemic thrombolysis: OR 0.28, 0.09-0.85; ultrasound-assisted catheter-directed thrombolysis: OR 0.29, 0.10-0.82). No strategy showed a robust mortality reduction. Systemic thrombolysis increased major bleeding (OR 4.69, 2.63-8.34) and intracranial haemorrhage (OR 10.04, 1.28-78.73); ultrasound-assisted catheter-directed thrombolysis increased major bleeding (OR 2.83, 1.29-6.20). Large-bore aspiration thrombectomy ranked favourably for efficacy outcomes, but this signal was sparse, indirect versus anticoagulation, and PEERLESS-sensitive. Catheter-assisted aspiration thrombectomy ranked favourably for bleeding safety, but efficacy evidence was limited and uncertain. NMA-3 broadly supported the primary efficacy findings.Interpretation: Systemic thrombolysis and ultrasound-assisted catheter-directed thrombolysis reduce early clinical deterioration and treatment escalation in intermediate-high-risk pulmonary embolism, but mortality benefit is unproven. Systemic thrombolysis has an important bleeding penalty. Among device-based strategies, large-bore aspiration thrombectomy showed favourable efficacy rankings but PEERLESS-sensitive evidence, whereas catheter-assisted aspiration thrombectomy showed favourable bleeding-safety rankings but less certain efficacy evidence. Current evidence supports selective, risk-adapted reperfusion rather than routine escalation for all intermediate-risk pulmonary embolism.

  • Open Access

    AngioJet rheolytic thrombectomy coupled with dose-reduced rt-PA for massive inferior vena cava filter-related thrombosis: A single-center retrospective study

    by Maofeng Gong, Qing Zhao, Rui Jiang, Zhengli Liu, Boxiang Zhao, Jie Kong, Xu He, Jianping Gu


  • Open Access

    Ferroptosis Related Prediction Model for Hepatocellular Carcinoma Patients Sensitive to Chemotherapy Embolization Therapy Based on Bioinformatics Analysis

    by Jiang Rui, Liu Zhengli, Fu Guanqi, Zhao Boxiang, Gong Maofeng, Lu Zhaoxuan, Zhou Yangyi, Chen Liang, Su Haobo, Lou Wensheng, et al.

    Objective: The objective of this study was to develop a predictive model that can help with effective transcatheter arterial chemoembolization (TACE) in treating hepatocellular carcinoma by identifying ferroptosis-associated genes. Methods: In this study, the GSE104580 dataset from the GEO database was analyzed to identify significantly differentially expressed genes (DEGs), which were then used to identify genes associated with chemoembolization sensitivity and ferroptosis using the weighted gene co-expression network analysis (WGCNA). These genes were then used to construct a TACE treatment sensitivity prediction model using lasso regression. Immune infiltration analysis was also conducted, and a hub mRNA, hub miRNA, and hub lncRNA interaction network was established. The TCGA dataset was used to construct a prediction model which was validated by ICGC dataset. Results: Using the GSE104580 dataset, a total of 2689 DEGs were screened, resulting in the identification of 37 genes. Protein-protein interaction (PPI) network analysis was performed based on these genes, and key genes involved in predicting TACE treatment sensitivity for liver cancer were identified through GO, KEGG, and GSEA analyses. Using the lasso regression method, six hub genes were identified: GLS2, CDKN1A, GPT2, ASNS, SLC38A1, and SLC2A1. Two distinct ferroptosis patterns were identified based on these hub genes, and immune infiltration analysis was conducted to further investigate potential associations with liver cancer. Additionally, a hub mRNA, miRNA, and LncRNA interaction network was constructed using data from miRTarBase, TarBase, and Starbase databases. Utilizing a 6-gene signature, two distinct risk groups were identified. Remarkably, patients classified within the high-risk group exhibited a significant decrease in overall survival when compared to their low-risk counterparts (P < 0.001 in the TCGA cohort and P = 0.013 in the ICGC cohort). In addition, the predictive capacity of this signature was further validated by receiver operating characteristic (ROC) curve analysis. Conclusion: This study suggests that the six hub genes identified in this research could serve as important targets for improving liver cancer prognosis. Additionally, these genes can be utilized to construct effective TACE sensitive prediction models to help clinicians in treating hepatocellular carcinoma.

  • Open Access

    Rheolytic thrombectomy using an AngioJet ZelanteDVT catheter or a Solent Omni catheter for patients with proximal vein thrombosis

    by Maofeng Gong, Guanqi Fu, Zhengli Liu, Yangyi Zhou, Jie Kong, Boxiang Zhao, Wensheng Lou, Jianping Gu, Xu He

    Purpose: The present study aimed to investigate the preliminary safety and efficacy of rheolytic thrombectomy (RT) using an AngioJet Zelante DVT catheter or a Solent Omni catheter for acute proximal deep vein thrombosis (DVT). Material and methods: We conducted a retrospective review of 40 patients who were treated with an AngioJet RT between January 2019 and January 2021, and then the patients were divided into the ZelanteDVT group (n = 17) and the Solent group (n = 23). Data on demographics, clinical characteristics, technical success, clinical success, complications, and early follow-up were analysed. Results: No significant differences regarding demographics were detected (all p > .05). The technical success rates were both 100%. The ZelanteDVT group had a shorter duration of RT and a higher primary RT success than the Solent group (all p < .05), and the percentage of adjunctive catheter-directed thrombolysis (CDT) was 29.4% in the ZelanteDVT group, which was significantly lower than the 73.9% in the Solent group (p = .010). The clinical success rates for the ZelanteDVT group and Solent group were 100% (17/17) and 95.7% (22/23), respectively, and these values were high in the two groups (p > .05). Apart from transient macroscopic haemoglobinuria occurring in all the patients during the first 24 hours post-RT, none of the patients in either group suffered other procedure-related adverse events or major complications. Minor complications included bleeding events in 21.7% (5/23) of the patients in the Solent group and one (5.9%) patient in the ZelanteDVT group (p > .05). At 6 months, the frequency of PTS was 5.9% (1/17) in the ZelanteDVT group and 17.4% (4/23) in the Solent group (p > .05). Conclusion: Both catheters are safe and effective in managing patients with proximal DVT, thus leading to improved clinical outcomes with few complications. The ZelanteDVT catheter was more effective than the Solent catheter in thrombectomy, thus allowing for faster extraction of the DVT with a shorter run time and lower proportions of patients with adjunctive CDT.


  • Angiojet pharmacomechanical thrombectomy versus anticoagulant therapy alone in massive cancer-associated thrombosis: a single centre retrospective cohort study

    by Maofeng Gong, Guanqi Fu, Zhengli Liu, Boxiang Zhao, Jie Kong, Xu He, Jianping Gu

    The therapeutic regimen option for the cancer-associated thrombosis (CAT) patients is still a major clinical challenge. The present study aimed to investigate the safety and efficacy of pharmacomechanical catheter-directed thrombolysis (PCDT) with AngioJet treatment compared with the conventional anticoagulation alone therapy in the patients with CAT. We retrospectively reviewed the patients who underwent PCDT and/or anticoagulation for the treatment of CAT between August 1, 2016 and March 1, 2022. Each patient was divided into the PCDT group or the anticoagulation alone group. The baseline demographics, comorbidities, clinical characteristics, treatment details, course data were reviewed. A total of 51 eligible patients were included, of whom 21 were in PCDT group (mean age, 60.1 ± 13.0 years; 52.4% male) and 30 in anticoagulation alone group (mean age, 66.6 ± 11.1 years; 50.0% male). No significant differences regarding age, sex, onset time, limb characteristics, cancer conditions or risk factors were detected (p > .05). After PCDT, grade III lysis was achieved in 8 and grade II lysis in 11 patients. Clinical success was achieved in 90.5% (19/21) patients. The symptoms of leg pain and swelling were significantly improved in both groups. Except for transient macroscopic hemoglobinuria occurring in PCDT group, none of all patients suffered from procedure-related and major complications. Minor complications such as bleeding events occurred in 23.8% (5/21) of patients in PCDT group compared with 10.0% (3/30) in anticoagulation alone group (p > .05). At the 6-month follow-up, iliofemoral patency was found an absolute risk reduction of 37.9% (70.0 vs. 32.1%) (95% CI: 1.183–4.008%; P = 0.010). The incidence of mild PTS was 5.0% (1/20) in PCDT group compared with 10.7% (3/28) in anticoagulation alone group (p > .05). The PCDT is a safe and effective modality in managing patients with CAT, leading to improved clinical outcomes with a low complication. The PCDT was more effective than anticoagulation alone in massive symptom relief and venous patency.


  • Open Access

    Risk factors and a predictive model for nonfilter-associated inferior vena cava thrombosis in patients with lower extremity deep vein thrombosis

    by Maofeng Gong, Jie Kong, Yadong Shi, Boxiang Zhao, Zhengli Liu, Xu He, Jianping Gu

    Objective: Nonfilter-associated inferior vena cava thrombosis (IVCT) is an under-recognized but severe state of venous thromboembolism. The aims of this study were to investigate risk factors and develop a prediction model based on clinical data and imaging findings to evaluate the probability of IVCT in patients with lower extremity deep vein thrombosis (LEDVT).Methods: A single-center retrospective cohort study was conducted. We analyzed the clinical data and multimodal imaging findings of consecutive patients with confirmed LEDVT between February 2016 and January 2022. The demographics, presentation of LEDVT, laboratory examination, thrombus characteristics, comorbidities and risk factors for LEDVT, and imaging findings were analyzed using an independent t-test, Chi-square test, Fisher's exact test, and regression analysis to determine the univariable and multivariable associations and to establish a predictive model to assess the probability of IVCT.Results: A total of 267 eligible patients were included, of whom 40 were in the IVCT group and 227 were in the non-IVCT group. The incidence of nonfilter-associated IVCT was 15.0% (40/267). Age < 63.5 years [odds ratio (OR) 2.54; 95% confidence interval (CI), 1.10–5.85, p = 0.029], male sex (OR 2.82; 95% CI, 1.19–6.72, p = 0.019), proximal DVT (OR 8.21; 95% CI, 1.01–66.76, p = 0.049), bilateral DVT (OR 7.30; 95% CI, 3.28–16.21, p < 0.001), and D-dimer >4.72 μg/ml (OR 4.64; 95% CI, 1.80–11.72, p = 0.001) were risk factors for IVCT's occurrence. Then, we established a prediction model based on these risk factors. The diagnostic efficiency [area under the curve (AUC) of receiver operating characteristic (ROC) curve was 0.858] for predicting IVCT was superior to that of isolated risk factors, including age < 63.5 years (AUC of ROC curve was 0.624) or D-dimer >4.72 μg/ml (AUC of ROC curve was 0.656).Conclusion: Age < 63.5 years, male sex, proximal LEDVT, bilateral LEDVT and D-dimer >4.72 μg/ml were risk factors. The diagnostic efficiency of the predictive model for predicting IVCT was superior to that of a single risk factor alone. It may be used for predicting the probability of nonfilter-associated IVCT in patients with LEDVT.


  • Outcomes of Fluoroscopy-Guided Percutaneous High Ligation of the Great Saphenous Vein Combined With Foam Sclerotherapy for Symptomatic Great Saphenous Veins

    by Jie Kong, Zhengli Liu, Guanqi Fu, Yan Li, Guoping Chen, Wensheng Lou, Boxiang Zhao, Maofeng Gong, Zhaoxuan Lu, Yangyi Zhou, et al.